Prevention of skeletal related events in adult patients. Treatment of adult patients w/ tumour-induced hypercalcaemia.
Dosage/Direction for Use
Prevention of skeletal related events in patientsAdult & elderly 4 mg every 3-4 wk. Treatment of tumour-induced hypercalcaemiaAdult & elderly 4 mg single dose. Renal impairment CrCl >60 mL/min 4 mg, CrCl 50-60 mL/min 3.5 mg, CrCl 40-49 mL/min 3.3 mg, CrCl 30-39 mL/min 3 mg.
Contraindications
Hypersensitivity to zoledronic acid or to other bisphosphonates. Lactation.
Special Precautions
Patients, especially the elderly, should be appropriately hydrated before administration of zoledronic acid. Avoid overhydration. Assess serum creatinine levels prior to administration. Monitor serum levels of Ca, phosphate & Mg after initiating therapy. Osteonecrosis of the jaw & external auditory canal. Bone, joint &/or muscle pain. Atypical subtrochanteric & diaphyseal femoral fractures. Hypocalcaemia. Concomitant use w/ other bisphosphonate. Renal impairment. May affect ability to drive & use machines. Pregnancy.
Additive effect (lowering of serum Ca level) w/ aminoglycosides. Use w/ caution when administered concomitantly w/ medicines that could affect renal function. Increased risk of renal dysfunction w/ thalidomide in multiple myeloma patients. Increased incidence of osteonecrosis of the jaw w/ anti-angiogenic medicinal products.
Manage Account
Change Password
Sign Out
